



Post Authorisation Assessments

Moxapulvis 500 mg/g Powder for Use in Drinking Water Vm 19968/3001

02 April 2026	Submission of an updated Ph. Eur. CEP. Deletion of a non-significant specification parameter. Deletion of a non-significant specification parameter.
30 September 2025	Addition of a new therapeutic indication for pigs. One-off alignment of the product information with version 9.0* of the QRD templates.
30 April 2025	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
02 April 2025	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
08 November 2024	Minor change to an approved test procedure for finished product (GB).
08 November 2024	Minor change to an approved test procedure for the finished product (NI).
25 April 2023	Unlimited renewal.
22 December 2020	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer. Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer. Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.
03 September 2019	Change in shape or dimensions of the container or closure (immediate packaging).